This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


AstraZeneca PLC

Drug Names(s): melagatran/ximelagatran

Description: Exanta (ximelagatran) is an oral direct thrombin inhibitor. The mechanism of action of Exanta is to inhibit the activity of a clot-forming enzyme called thrombin, which is critical to the final step in the formation of blood clots.

Exanta News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug